Diagnosis · Testing · Chronic Lyme
You've been sick for months — maybe years. Fatigue that sleep doesn't fix, joint pain that moves around your body, brain fog so thick you struggle to finish a sentence. Your doctor orders a Lyme disease test. It comes back negative. End of conversation.
For hundreds of thousands of patients across North America, this is where the journey stalls. Not because they don't have Lyme disease. But because the test being used was never designed to find it at the stage they're in.
Understanding why standard Lyme tests fail chronic patients is the first step toward getting an accurate picture of what's actually happening in your body.
When a doctor suspects Lyme disease, the CDC recommends a two-tier testing approach. First, an ELISA (enzyme-linked immunosorbent assay) test screens for antibodies against Borrelia burgdorferi, the bacterium that causes Lyme. If that comes back positive or equivocal, a Western blot test is run to confirm.
On paper, this sounds thorough. In practice, it has a fundamental flaw — one that has been documented in peer-reviewed literature for decades but has been slow to change clinical practice.
This is the core issue. ELISA and Western blot are antibody tests — they detect whether your immune system has produced antibodies against Borrelia. They do not detect the bacteria itself.
This creates an immediate problem for chronic patients. By the time Lyme disease has persisted for months or years, Borrelia has developed sophisticated strategies to evade immune detection. The bacteria can:
When Borrelia suppresses or evades your immune response, your body produces fewer antibodies. Fewer antibodies mean a weaker signal on the ELISA — often falling below the positive threshold entirely.
Key insight: A negative antibody test does not mean you don't have Borrelia infection. It may simply mean your immune system's response has been suppressed or changed over time — which is itself a hallmark of chronic Lyme disease.
When the two-tier protocol was developed, the antibody thresholds were set using data from patients with early Lyme disease — people infected for days or weeks who had the characteristic bull's-eye rash. These patients mount a vigorous, detectable immune response.
Chronic Lyme patients are biologically different. Their immune response has often been dysregulated for years. Using early-stage thresholds to evaluate a chronic patient is like using a sprint time to assess a marathon runner — the measurement tool doesn't fit the situation.
Standard Lyme tests are designed primarily to detect antibodies against Borrelia burgdorferi sensu stricto — the strain predominant in northeastern North America. But the Borrelia genus includes over 300 species and subspecies worldwide.
In Europe, Borrelia afzelii and Borrelia garinii are common culprits. In the western United States, Borrelia miyamotoi is increasingly implicated in Lyme-like illness. Patients infected with these strains may test completely negative on a standard panel because the test simply isn't looking for the right antibodies.
For a Western blot to be considered positive, the CDC requires a specific number of "bands" — protein signatures indicating Borrelia antibodies. The current criteria require 5 of 10 possible IgG bands, or 2 of 3 IgM bands.
Many clinicians and researchers argue these criteria are too restrictive. A patient showing 4 IgG bands — counted as negative — is still producing antibodies against four distinct Borrelia proteins. That is biologically significant, but the protocol disregards it entirely.
The interpretation criteria were set in the 1990s and have not been substantially updated despite decades of additional research into Borrelia biology and persistent infection.
Patients who receive a negative standard test but continue to present with classic Lyme symptoms have several more sensitive options to discuss with an integrative or Lyme-literate physician:
Research consistently shows that the longer Borrelia remains untreated, the more deeply it embeds itself in tissue, the more established its biofilm communities become, and the more dysregulated the immune response grows.
Patients dismissed after a negative ELISA often spend years — sometimes decades — cycling through diagnoses of fibromyalgia, chronic fatigue syndrome, multiple sclerosis, or anxiety before finding a clinician who takes a comprehensive view of their history and symptoms.
That delay has real biological consequences. It is not simply a matter of feeling unwell longer. It is the difference between an infection that responds to treatment and one that has become deeply entrenched in the body's tissues and immune architecture.
At our clinic in Tijuana, we work with patients who have often already received negative standard tests. Many have been told their symptoms are psychosomatic, or that Lyme disease doesn't persist after standard antibiotic treatment.
Our evaluation goes beyond antibody levels. We assess the immune system's functional state — specifically the balance of regulatory T cells (Tregs), which play a central role in the immune dysregulation seen in chronic Lyme. A depleted or dysfunctional Treg population is itself a clinical signal, one that standard Lyme testing cannot detect but that points clearly toward persistent infection and immune disruption.
We also take an exhaustive history. The pattern and progression of symptoms, the circumstances of potential exposure, prior treatment responses, and co-infection history all contribute to a clinical picture that no single blood test can capture.
If you have been told your Lyme test is negative but your symptoms persist, that negative result is a data point — not a conclusion.
Our team reviews every patient case individually. If standard testing has failed to explain your symptoms, we'd like to hear your story.
Check My Eligibility